$BGBIO We are a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL in aggressive diseases
Bergen, Norway / Oxford, UK
Joined December 2016
- Tweets171
- Following45
- Followers776
- Likes36
Our CEO, Martin Olin, comments on today’s Q1 2022 results.
You can read the report in full here: ow.ly/M3Mp50Jgjru
#FinancialResults #BGBIO
Today we announced our Q1 2022 results. A presentation by BerGenBio’s senior management team will take place today at 10 am CEST - watch the webcast here: ow.ly/K3Sb50JgaEI
Read the full PR here: ow.ly/lEXb50JgaEL
#FinancialResults
We’re pleased to announce complete data analysis from the #ACCORD2 phase II study of #bemcentinib in combination with #SoC therapy in hospitalized #COVID19 patients. The primary endpoint of improved clinical response was met.
Read the full release here: bergenbio.com/bergenbio-anno…
The data presented at #ECCMID2022 today demonstrate that bemcentinib treatment provides early and sustained protection, limiting clinical deterioration in moderate to severe #COVID19 patients.
Read the full release here: ow.ly/3eXV50IR2x7
#BGBIO #oncology #Presenation
We’re presenting data from our BGBC020 clinical trial in hospitalised #COVID19 patients today at #ECCMID2022.
Read the full release here: tools.eurolandir.com/tools/P…
2
Yesterday we announced a publication in Cell Reports Medicine on #AXL as a driver of immune suppression in STK11/LKB1 mutated NSCLC.
STK11 is associated with poor treatment outcomes in NSCLC. There are currently no STK11-targeted therapies .
Link: bit.ly/3KRhDgq
BerGenBio’s CEO, Martin Olin, comments on today’s Q4 and FY 2021 results.
You can view the report in full here: bergenbio.com/wp-content/upl…
#financialresults #BGBIO
1
4
Today we announced our Q4 and FY 2021 #results. A presentation by BerGenBio’s senior management team will take place today at 10am CET. If you would like to watch the live webcast, follow this link: bit.ly/3sJS0GU
Read the press release here: bit.ly/3gR2QVO
We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the @EU_SolidAct trial.
Read the release here: bergenbio.com/investors/stoc…
#AXL
This morning BerGenBio announced a license agreement with @UTSWNews
The exclusive license is related to the treatment of Non-Small Cell Cancer (NSCLC) patients with #STK11 mutations and supports the Company’s existing IP position.
Read here: bergenbio.com/bergenbio-anno…
2
CEO Martin Olin comments on BerGenBio’s Q3 2021 results, out today.
You can view the report in full here: bergenbio.com/wp-content/upl…
#financialresults #BGBIO
We are pleased to announce our Q3 2021 results. A presentation by BerGenBio’s senior management team will take place today at 10am CET.
For the full webcast: ow.ly/b1V150GOuqh
For the full PR: ow.ly/GM0650GOuqi
#oncology #financialresults #BGBIO
Register to watch BerGenBio's Satellite Symposium taking place today at the EHA SWG at 17:30 CET here: ehaweb.org/meetings/swg-on-g…
#EHA #hematology
1
2
September is Blood Cancer Awareness Month. Blood cancer affects millions and BerGenBio shares the vision of raising awareness and understanding of blood cancers, including #AML, the most common form of acute leukaemia.
Learn more here: bit.ly/3EcROVs
#BCAM2021
Today we announced our financial results for the second quarter and first half of 2021.
A presentation by BerGenBio's senior management team will take place today at 10:00 am CET at this link: channel.royalcast.com/landin…
Read the full announcement here: bit.ly/3ANrcYv
1
2
Yesterday we were honoured to host @IselinNybo the Norwegian Minister of Trade and Industry, at BerGenBio - see some pictures from the visit below. #Norway #NorweiganBiotech #BGBIO
Our CEO, Richard Godfrey, comments on a very exciting and encouraging week for #BerGenBio. To learn more about the progress we’ve made this week and our outlook, watch the video here: bergenbio.com/
#bemcentinib #oncology #immunooncology
Today we are pleased to be presenting preliminary data at the EHA Virtual Meeting, showing that #bemcentinib in combination with LDAC has shown encouraging preliminary updated survival data in our Phase II study in relapsed #AML patients. Read more here: bit.ly/35habIp
Want to hear more about BerGenBio’s latest COVID-19 updates? Have a read of this in-depth piece from Cormac Sheridan at BioWorld, featuring commentary from CEO Richard Godfrey.
bit.ly/3u7Rn8P
#bemcentinib #COVID19